SCHEMBL2350693

SCHEMBL2350693

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1ccc(OC(F)(F)F)c(-c2ccc(C(=O)O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42
JAK2 O60674 2/20 0.42
BCL9 O00512 2/20 0.41
CTNNB1 P35222 2/20 0.41
F11 P03951 2/20 0.41
KLK1 P06870 1/20 0.41
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC8 Q9BY41 1/20 0.39
SSTR5 P35346 1/20 0.39
P2RY14 Q15391 1/20 0.39
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2350699 1.00 NPC1 (0.52) NPC1MEN1KMT2ALMNANPSR1
SCHEMBL2344552 0.89 NPC1 (0.48) NPC1MEN1KMT2ALMNANPSR1
SCHEMBL2344558 0.89 NPC1 (0.48) NPC1MEN1KMT2ALMNANPSR1
SCHEMBL13212099 0.89 NPC1 (0.46) NPC1MEN1KMT2ALMNANPSR1
SCHEMBL12394319 0.85 BCL9 (0.47) BCL9CTNNB1F11KLK1ABL1
SCHEMBL2907510 0.82 F11 (0.48) NPC1BCL9CTNNB1F11KLK1
SCHEMBL2346140 0.81 NPC1 (0.42) NPC1MEN1KMT2ALMNAABL1
SCHEMBL2346149 0.81 NPC1 (0.42) NPC1MEN1KMT2ALMNAABL1
SCHEMBL2347121 0.80 NPC1 (0.66) NPC1MEN1KMT2ALMNANPSR1
SCHEMBL2347111 0.80 NPC1 (0.66) NPC1MEN1KMT2ALMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008303-B2 e.g. 6-Methyl-biphenyl-3,4'-dicarboxylic acid 4'-[(3-bromo-phenyl)-amide]-[(4 morpholin-4-yl-phenyl)-amide]; viricide; with other active viricide such as interferon or ribavirin ASTRAZENECA AB (SE) 2011-08-30 US disclosed
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 NPC1 146/4885MEN1 3163/4885KMT2A 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.